“…Several previous randomized controlled clinical trials found that SDF can accelerate the intestine transmission speed and improve the symptoms of constipation and the incidence of abdominal distension 27‐30 . In our trial, we confirmed that supplemental SDF reduces the incidence of constipation and abdominal distension in patients with SAP.…”
Background
Feeding intolerance of enteral nutrition (EN) frequently occurs in patients with severe acute pancreatitis (SAP) because of intestinal motility disorders. Soluble dietary fiber (SDF) modulates the intestinal motility. The present study examined whether SDF can improve intestinal motility and permeability, and thereby reduce feeding intolerance, in patients with SAP.
Methods
This study was a single‐blind, randomized, controlled, single‐center trial. Forty‐nine patients with SAP were included. The control and SDF groups received the same EN solution via a nasojejunal tube. The SDF group additionally received 20‐g/d polydextrose. The primary outcome was the time to reach the energy goal. Follow‐up was continued for 28 days after admission or until discharge from the hospital.
Results
Among 49 randomized patients, 46 patients (n = 22, control group; n = 24, SDF group) were included in the intent‐to‐treat analysis. The time to reach the energy goal was 7.00 (6.00, 8.25) days and 5.00 (4.25, 6.00) days in the control and SDF groups, respectively (P < 0.001). The rates of feeding intolerance were significantly reduced in the SDF group (59.09% vs 25.00%, P < .05). SDF was associated with decreases in the incidence of abdominal distension (72.73% vs 29.17%, P < .01), diarrhea (40.91% vs 8.33%, P < .05), and constipation (72.73% vs 12.50%, P < .001). The time to first flatus and first defecation were significantly shorter in the SDF group (P < .001). The intestinal mucosal barrier function and levels of gastrointestinal hormone were improved by SDF, as evidenced by significantly reduced blood levels of diamine oxidase, D‐lactic acid, endotoxin, and vasoactive intestinal peptide (P < .05).
Conclusions
SDF shortens the time to reach the energy goal during EN and improves intestinal permeability and motility disorders, thus reducing the incidence of feeding intolerance in SAP patients.
“…Several previous randomized controlled clinical trials found that SDF can accelerate the intestine transmission speed and improve the symptoms of constipation and the incidence of abdominal distension 27‐30 . In our trial, we confirmed that supplemental SDF reduces the incidence of constipation and abdominal distension in patients with SAP.…”
Background
Feeding intolerance of enteral nutrition (EN) frequently occurs in patients with severe acute pancreatitis (SAP) because of intestinal motility disorders. Soluble dietary fiber (SDF) modulates the intestinal motility. The present study examined whether SDF can improve intestinal motility and permeability, and thereby reduce feeding intolerance, in patients with SAP.
Methods
This study was a single‐blind, randomized, controlled, single‐center trial. Forty‐nine patients with SAP were included. The control and SDF groups received the same EN solution via a nasojejunal tube. The SDF group additionally received 20‐g/d polydextrose. The primary outcome was the time to reach the energy goal. Follow‐up was continued for 28 days after admission or until discharge from the hospital.
Results
Among 49 randomized patients, 46 patients (n = 22, control group; n = 24, SDF group) were included in the intent‐to‐treat analysis. The time to reach the energy goal was 7.00 (6.00, 8.25) days and 5.00 (4.25, 6.00) days in the control and SDF groups, respectively (P < 0.001). The rates of feeding intolerance were significantly reduced in the SDF group (59.09% vs 25.00%, P < .05). SDF was associated with decreases in the incidence of abdominal distension (72.73% vs 29.17%, P < .01), diarrhea (40.91% vs 8.33%, P < .05), and constipation (72.73% vs 12.50%, P < .001). The time to first flatus and first defecation were significantly shorter in the SDF group (P < .001). The intestinal mucosal barrier function and levels of gastrointestinal hormone were improved by SDF, as evidenced by significantly reduced blood levels of diamine oxidase, D‐lactic acid, endotoxin, and vasoactive intestinal peptide (P < .05).
Conclusions
SDF shortens the time to reach the energy goal during EN and improves intestinal permeability and motility disorders, thus reducing the incidence of feeding intolerance in SAP patients.
“…PDX has been reported in several studies to increase fecal bulk and soften stools [11,12,13,14,15,16,17,18,19]. Prebiotic fibers such as PDX also stimulate intestinal peristalsis and increase defecation frequency [13,14,20,21]. However, there are few studies on the effects of PDX on shortening total or colonic transit time (CTT), and the results have been inconclusive [13,18,19].…”
Section: Introductionmentioning
confidence: 99%
“…The measurement of CTT is considered the standard method for examining bowel movements [20]. Notably, reported symptoms and quality of life ratings are not clearly or consistently related to a slow transit time but correlate consistently with an increase in fecal mass [18,19].…”
The addition of fiber is one of the most important dietary means to relieve constipation through lifestyle modification. Polydextrose (PDX) has been reported in several studies to increase fecal bulk, soften stools, and increase the number of defecations. However, there are few studies on the effect of PDX on colonic transit time (CTT). Therefore, the aim of this study was to demonstrate the effect of PDX on CTT and other aspects of gastrointestinal function during two weeks (Day 1 to Day 14), preceded by a 2-week run-in period (Day -14 to Day -1). A total of 192 adults who were diagnosed with functional constipation per Rome III criteria were recruited for the study. Participants were randomized equally into 4 groups (12 g, 8 g, or 4 g of PDX or placebo per day). The primary endpoint was CTT, assessed using radio-opaque markers and abdominal X-rays on Day 0, the baseline; and Day 15, the end of the intervention. Secondary outcomes that were measured using inventories were the patient assessment of constipation symptoms and quality of life, bowel function index, relief of constipation, bowel movement frequency (BMF), stool consistency, degree of straining, and proportion of bowel movements. Ancillary parameters and harms were also evaluated. The recruited population was not sufficiently constipated (e.g., baseline values for CTT and BMF of 42 h and 8.7 BMF/week, respectively). Despite this limitation, our results demonstrated an increased number of bowel movements when supplemented with PDX at a dosage of 12 g per day for 2 weeks. This dosage also consistently improved the secondary outcomes that were measured using inventories at Day 15, compared with the baseline. No serious or significant adverse events were reported during the study.
“…In constipated adult Japanese dialysis patients, those who received 10 g of polydextrose daily for 8 weeks significantly improved their bowel habits. Stool frequency increased from 3 to 7.5 times weekly with no adverse GI effects (p<0.01) 69 .…”
El estreñimiento funcional es uno de los trastornos gastrointestinales más frecuentes en los niños y adultos. El aumento del consumo de agua y fibra son algunas de las recomendaciones mas comúnmente dadas a los pacientes. Una mayor ingesta de fibra se puede lograr a través del consumo de alimentos ricos en fibra dietética, o tomado en forma suplementaria. Además de las fibras que ocurren naturalmente en los alimentos, la Administración de Drogas y Alimentos (FDA) de los Estados Unidos ha aprobado más de 14 fibras aisladas o sintéticas para su uso. Hoy en día existen pocas investigaciones que hayan estudiado el beneficio de todos estos tipos de fibra para el tratamiento del estreñimiento en niños y adultos. Esta revisión discute la evidencia de los diferentes tipos de fibra para el tratamiento del estreñimiento funcional en niños y adultos. (NeuroGastroLatam Rev. 2018;2:149-168).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.